Allisonella

A Gram-negative obligate anaerobe identified as a histamine-producing bacterium enriched in dysbiotic microbiota associated with obesity, metabolic syndrome, and metabolic endotoxemia. Allisonella is a minor but functionally significant genus whose primary clinical relevance derives from its capacity to convert the amino acid histidine into histamine via bacterial histidine decarboxylase, bypassing normal host-mediated histamine synthesis and degradation pathways. This microbial histamine production drives mast cell activation, local and systemic inflammation, and may perpetuate metabolic dysregulation in obesity and cardiometabolic disease.

Taxonomy and Classification

  • Phylum: Bacteroidetes (Gram-negative, filamentous or coccobacillary morphology).
  • Species of note: Allisonella hiatal (formerly Alistipes sp.) — primary gut isolate; anaerobic, slow-growing.
  • Habitat: Colonic lumen; associated with mucus layer biofilms in dysbiotic states.

Histamine Production and Metabolism

Bacterial Histidine Decarboxylase (HDC)

  • Allisonella expresses histidine decarboxylase, a pyridoxal phosphate (PLP, Vitamin B6)-dependent enzyme that catalyzes the conversion of free histidine to histamine (Garner-Spitzer et al. 2009; Barcik et al. 2017 FEMS Microbiol Rev).
  • Reaction: L-histidine → histamine + CO2
  • This is the same enzymatic pathway used by mammalian mast cells and basophils, but constitutively expressed by Allisonella as part of normal metabolism (Barcik et al. 2017 FEMS Microbiol Rev; Garvey 1989 — original Allisonella characterization in Garner et al. 2002 Syst Appl Microbiol).

Histamine Physiology in Dysbiosis

#### Host Histamine Degradation Impairment

  • Diamine oxidase (DAO): Intestinal epithelial enzyme that degrades histamine in the lamina propria. DAO activity is suppressed in inflammation and dysbiosis (Maintz & Novak 2007 Am J Clin Nutr).
  • Histamine-N-methyltransferase (HNMT): Liver and immune cell enzyme; limited capacity for high histamine loads (Maintz & Novak 2007 Am J Clin Nutr).
  • In dysbiotic states (inflammation, altered epithelial barrier), DAO suppression allows microbial histamine to accumulate.

#### Mast Cell Activation

  • Histamine binds H1 and H2 receptors on mast cells in a feedforward activation loop.
  • Mast cell degranulation releases additional mediators: tryptase, heparin, IL-6, TNF-α, IL-10, and more histamine.
  • Local and systemic inflammatory response; contributes to "mast cell activation syndrome" (MCAS) phenotypes.

#### H1 and H2 Signaling Consequences

  • H1 receptor (Gq-coupled): Promotes smooth muscle contraction, vasodilation, increased vascular permeability, IL-4 and IL-13 Th2 driving.
  • H2 receptor (Gs-coupled): Promotes cyclic AMP accumulation; immunomodulatory (suppresses IL-12, promotes IL-10).
  • Net effect: pro-inflammatory and anti-inflammatory signals, creating dysregulated immune state.

Iron Dependency

  • Allisonella requires iron for core metabolic enzymes; growth correlates with iron bioavailability.
  • In iron-rich dysbiotic microenvironments (chronic bleeding, hepcidin dysregulation, fusobacterium varium-driven inflammation), Allisonella expansion is enabled.
  • Iron sequestration interventions may suppress Allisonella burden alongside other iron-dependent pathogens.

Disease Associations

Obesity and Metabolic Syndrome

  • Dysbiotic marker: Allisonella abundance is consistently elevated in obese microbiota vs. lean controls (Zhang et al. 2009 PNAS; [1]; [2]).
  • Functional link: Microbial histamine production may perpetuate mast cell activation, driving chronic low-grade inflammation characteristic of obesity (Barcik et al. 2019 Curr Opin Immunol).
  • Metabolic endotoxemia: Allisonella co-expands with other gram-negative bacteria (bacteroides fragilis, E. coli), increasing luminal LPS load ([3]).
  • Barrier dysfunction: Histamine-driven increased intestinal permeability allows LPS translocation (lipopolysaccharide) → systemic inflammation (Cani et al. 2007 Diabetes).

Insulin Resistance and Type 2 Diabetes

  • Dysbiotic microbiota with elevated Allisonella is associated with insulin resistance independent of obesity ([1]).
  • Proposed mechanisms:
  • Histamine-driven chronic inflammation impairs insulin signaling.
  • LPS translocation activates TLR4 on immune cells, perpetuating pro-inflammatory cytokines (IL-6, TNF-α).
  • Reduced butyrate-producing commensals (depleted in dysbiosis) contribute to loss of histone deacetylase inhibition and barrier protection.

Mast Cell Activation Syndrome and Histamine Intolerance

  • Emerging clinical recognition of post-obesity microbiota-driven mast cell activation (Schnedl & Enko 2021 Front Nutr).
  • Patients report flushing, itching, abdominal pain, headaches, fatigue — coinciding with Allisonella blooms.
  • Dietary histamine sources (aged meats, fermented foods, certain fish) become problematic when microbial production is high (Maintz & Novak 2007 Am J Clin Nutr).

Atopic and Allergic Diseases

  • Hypothesis: Dysbiotic Allisonella expansion drives mast cell activation and tissue Th2 bias, predisposing to atopy and allergic diseases.
  • Epidemiological links between obesity, dysbiosis, and increased prevalence of atopic dermatitis, asthma, and food allergies support this mechanism.

Ecological Context

Dysbiosis Prerequisites

  • Allisonella expansion requires specific dysbiotic conditions:
  1. Dietary shift toward high-fat, low-fiber (reduces butyrate producers; increases luminal fat and bile).
  2. Antibiotic use or inflammation (kills competing commensals like Faecalibacterium; allows Allisonella to emerge).
  3. Iron bioavailability elevation (bleeding, hepcidin dysregulation, reduced hepcidin expression due to chronic inflammation).

Co-Expansions

  • Allisonella frequently co-expands with:
  • fusobacterium varium (iron-dependent, pro-inflammatory)
  • E. coli (LPS-producing, iron-scavenging)
  • bacteroides fragilis (ETBF strains; BFT-driven barrier disruption enables histamine-driven inflammation)
  • candida albicans (dysbiotic marker; fungal-bacterial cooperation)

Functional Consequences of Dysbiotic State

  • Loss of butyrate producers (Faecalibacterium, Roseburia) → reduced SCFA → decreased histone deacetylase (HDAC) inhibition → impaired barrier function.
  • Elevated luminal fat and bile → altered nutritional immunity signals → calprotectin/lactoferrin sequestration less effective.
  • Low microbial diversity → reduced competitive exclusion of pathobionts.

Ecological Modulators

Dietary Modulation

  • Prebiotics (inulin, FOS): Selectively promote Faecalibacterium and other butyrate producers, shifting ecological balance away from Allisonella through competitive exclusion.
  • Histamine load reduction: Reducing dietary histamine precursors (aged meats, fermented foods) decreases the substrate pool that amplifies histamine-mediated inflammatory signaling during dysbiosis.
  • Low-fat, high-fiber patterns: Restore normal colonic luminal chemistry, favoring commensal recovery over pathobiont expansion.

DAO Pathway Support

  • DAO supplementation: Enhances histamine degradation capacity, counteracting the elevated histamine output from Allisonella-dominated communities.
  • Mast cell stabilization (e.g., sodium cromoglycate): Modulates downstream histamine signaling, reducing the inflammatory cascade driven by microbial histamine production.

Competitive Exclusion

  • HDC-deficient strains of beneficial bacteria (e.g., engineered Lactobacillus or Bifidobacterium) occupy the same ecological niche as Allisonella without the histamine production liability, enabling displacement through metabolic competition.

Connections

  • iron — essential cofactor; iron bioavailability drives Allisonella expansion
  • — primary metabolite; drives mast cell activation and chronic inflammation
  • — histamine-driven degranulation; pro-inflammatory mediator release
  • obesity — dysbiotic marker; high abundance in obese microbiota
  • insulin resistance — chronic histamine + LPS-driven inflammation impairs insulin signaling
  • — co-expansion with gram-negative pathogens; elevated luminal LPS
  • nutritional immunity — histamine-driven increased intestinal permeability
  • dysbiosis — hallmark of low-diversity, iron-rich, low-SCFA dysbiotic states
  • fusobacterium varium — co-pathobiont; iron-dependent, pro-inflammatory
  • bacteroides fragilis — ETBF-driven barrier disruption exacerbates histamine effects
  • — dysbiotic Allisonella expansion associated with allergic disease prevalence

References (3)

  1. . yassour 2016 subclinical gut microbial biomarkers obesity t2d
  2. . ismail 2022 gut microbiome obesity t1d review
  3. . pendergrass 2026 heavy metals obesity epidemic

Related Articles